Physiologically based pharmacokinetic and toxicokinetic models

Principles and Methods of Toxicology: Fifth Edition

Volumn , Issue , 2007, Pages 231-292

  Krishnan, Kannan ^a   Andersen, Melvin E ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85132684098     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (286)

1. Abraham, M. H., Ibrahim, A., and Aeree, W. E., Jr. (2005): Air to blood distribution of volatile organic compounds: a linear free energy analysis. Chem. Res. Toxicol., 18: 904-911.
2. Abraham, M. H., Kamlet, M. J., Taft, R. W., Doherty, R. M., and Weathersby, P. K. (1985): Solubility properties in polymers and biological media. 2. The correlation and prediction of the solubilities of nonelectrolytes in biological tissues and fluids. J. Med. Chem., 28:865-870.
3. Abraham, M. H., and Weathersby, P. K. (1994): Hydrogen bonding. 30. Solubility of gases and vapors in biological liquids and tissues. J. Pharm. Sci., 83:1450-1456.
4. Andersen, M. E. (1981): A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors, Toxicol. Appl. Pharmacol., 60:509-526.
5. Andersen, M. E. (2003): Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol. Lett., 138:9-27.
6. Andersen, M. E., Clewell, H. J., III, and Gargas, M. L. (1995): Contemporary issues in toxicology. Applying simulation modeling in toxicology and risk assessment: a short perspective. Toxicol. Appl. Pharmacol., 133:181-187.
7. Andersen, M. E., Clewell, H. J., III, and Gargas, M. L. (1991): Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite carbon monoxide and blood carboxyhemoglobin in rats and humans. Toxicol. Appl. Pharmacol., 108:14-27.
8. Anderson, M. E., Clewell, H. J., III, Gargas, M. L., Smith, F. A., and Reitz, R. H. (1987): Physiologically based pharmacokinetics and risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol., 87:185-205.
9. Andersen, M. E., Eklund, C. R., Mills, J. J., Barton, H. A., and Birnbaum, L. S. (1997): A multicompartment geometric model of the liver in relation to regional induction of cytochrome P-450s. Toxicol. Appl. Pharmacol., 144: 135-144.
10. Andersen, M. E., Gargas, M. L., Jones, R. A., and Jenkins, L. J. (1980): Determination of the kinetic constants for metabolism of inhaled toxicants in vivo by gas uptake measurements. Toxicol. Appl. Pharmacol., 54:116.
11. Andersen, M. E., Green, T., Frederick, C. B., and Bogdanffy, M. S. (2002): Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate. Regul. Toxicol. Pharmacol., 36:234-245.
12. Andersen, M. E., and Keller, W. C. (1984): Toxicokinetic principles in relation to percutaneous absorption and cutaneous toxicity. In: Cutaneous Toxicity, edited by V. A. Drill and P. Lazar. Raven Press, New York, pp. 9-27.
13. Andersen, M. E., and Krishnan, K. (1995): Relating in vitro to in vivo exposures with physiologically based tissue dosimetry and tissue response models. In: Animal Test Alternatives: Refinement, Reduction, Replacement, edited by H. Salem. Marcel Dekker, New York, pp. 9-25.
14. Andersen, M. E., MacNaughton, M. G., Clewell, H. J., III, and Paustenbach, D. J. (1987): Adjusting exposure limits for long and short exposure period using a physicological pharmacokinetic model. Am. Indust. Hyg. Assoc. J., 48: 335-343.
15. Andersen, M. E., Mills, J. J., and Gargas, M. L. (1993): Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. Risk Anal., 13:25-36.
16. Andersen, M. E., and Sarangapani, R. (2001): Physiologically based clearance/extraction models for compounds metabolized in the nose: an example with methyl methacrylate. Inhal. Toxicol., 13:397-114.
17. Andersen, M. E., Sarangapani, R., Frederick, C. B., and Kimbell, J. S. (1999): Dosimetric adjustment factors for methyl methacrylate derived from a steady-state analysis of a physiologically based clearance-extraction model. Inhal. Toxicol, 11:899-926.
18. Andersen, M., Sarangapani, R., Gentry, R., Clewell, H., Covington, T., and Frederick, C. B. (2000): Application of a hybrid CFD-PBPK nasal dosimetry model in an inhalation risk assessment: an example with acrylic acid. Toxicol. Sci., 57:312-325.
19. Arms, A. D., and Travis, C. C. (1988): Reference Physiological Parameters in Pharmacokinetic Modeling, NTIS PB 88-196019. Office of Health and Environmental Assessment, U.S. Environmental Protection Agency, Washington, D.C.
20. Balaz, S., and Lukacova, V. (1999): A model-based dependence of the human tissue/blood partition coefficients of chemicals on lipophilicity and tissue composition. Quant. Structure-Activity Relat., 18:361-368.
21. Ball, R., and Schwartz, S. L. (1994): Cmatrix: software for physiologically based pharmacokinetic modeling using a symbolic matrix representation system. Comput. Biol. Med., 24:269-276.
22. Barton, H. A., Deisinger, P. J., English, J. C., Gearhart, J. M., Faber, W. D., Tyler, T. R., Banton, M. I., Teeguarden, J., and Andersen, M. E. (2000): Family approach for estimating reference concentrations/doses for series of related organic chemicals. Toxicol. Sci., 54:251-261.
23. Barton, H. A., Creech, J. R., Godin, S., Randall, G. M., and Seckel, C. S. (1995): Chloroethylene mixtures: pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. Toxicol. Appl. Pharmacol., 130:237-247.
24. Basak, S. C., Mills, D., Hawkins, D. M., and El-Marsi, H. A. (2003): Prediction of human blood- air partition coefficient: a comparison of structure-based and property-based methods. Risk Anal., 23:1173-1184.
25. Basak, S. C., Mills, D., Hawkins, D. M., and El-Marsi, H. A. (2002): Prediction of tissue-air partition coefficients: a comparison of structure-based and property-based methods. SAR QSAR Environ. Res., 13:649-665.
26. Béliveau, M., and Krishnan, K. (2003): In silico approaches for developing physiologically based pharma-cokinetic (PBPK) models. In: Alternative Toxicology Methods, edited by H. Salem and S. Katz. CRC Press, Boca Raton, FL, pp. 479-532.
27. Béliveau, M., Lipscomb, J., Tardif, R., and Krishnan, K. (2005): Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals. Chem. Res. Toxicol., 18:475-185.
28. Béliveau, M., Tardif, R., and Krishnan, K. (2003): Quantitative structure-property relationships for physiologically based pharmacokinetic modeling of volatile organic chemicals in rats. Toxicol. Appl. Pharmacol., 189:221-32.
29. Benignus, V. A., Boyes, W. K., and Bushnell, P. J. (1998): A dosimetric analysis of behavioral effects of acute toluene exposure in rats and humans. Toxicol. Sci., 43:186-195.
30. Bernillon, P., and Bois, F. Y., (2000): Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environ. Health Perspect., 108(Suppl.):883-893.
31. Bischoff, K. B. (1987): Physiogically based pharmacokinetic modeling. Drinking Water Health, 8:36-64.
32. Bischoff, K. B., Dedrick, R. L., Zakharo, D. S., and Long-streth, J. A. (1971): Methotrexate pharmacokinetics. J. Pharm. Sci., 60:1128-1133.
33. Björkman, S. (2003): Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models. J. Pharmacokinet. Pharmacodyn., 30:285-307.
34. Bogaards, J. J., Freidig, A. P., and van Bladeren, P. J. (2001): Prediction of isopropene diepoxide levels in vivo in mouse, rat, and man using enzyme kinetic data in vitro and physiologically based pharmacokinetic modeling. Chem. Biol. Interact., 138:247-265.
35. Bois, F. Y. (1999): Analysis of PBPK models for risk characterisation. Ann. N.Y. Acad. Sci., 895:317-337.
36. Bois, F. Y. (2000): Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ. Health Perspect., 108(Suppl. 2):307-316.
37. Bois, F. Y. (2000): Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics. Environ. Health Perspect., 108(Suppl. 2):275-282.
38. Bois, F. Y., Woodruff, T. J., and Spear, R. C. (1991): Comparison of three physiologically based pharmacokinetic models for benzene disposition. Toxicol. Appl. Pharmacol., 110:79-88.
39. Bois, F. Y., Zeise, L., and Tozer, T. N. (1990): Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats and humans. Toxicol. Appl. Pharmacol., 102:300-315.
40. Bond, J. A., Himmelstein, M. W., Seaton, M., Boogaard, P., and Medinsky, M. A. (1996): Metabolism of butadiene by mice, rats, and humans: a comparison of physiologically based toxicokinetic model predictions and experimental data. Toxicology, 113:48-54.
41. Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., and Belisle, R. P. (2005): Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Indust. Health, 13:407-484.
42. Byczkowski, J. Z., and Fisher, J. W. (1995): A computer program linking physiologically based model with cancer risk assessment for breast-fed infants. Comput. Methods Programs Biomed., 46:155-163.
43. Cahill, T. M., Cousins, I., and Mackay, D. (2003): Development and application of a generalized physiologically based pharmacokinetic model for multiple environmental contaminants. Environ. Toxicol. Chem., 22:26-34.
44. 1 mice and Syrian golden hamsters. Toxicol. Appl. Pharmacol., 114:162-165.
45. Caster, W. O., Poncelet, J., Simon, A. B., and Armstrong, W. B. (1956): Tissue weights of the rat. I. Normal values determined by dissection and chemical methods. Proc. Soc. Exp. Biol. Med., 91:122-126.
46. Chen, H. S. G., and Gross, J. F. (1979): Estimation of tissue to plasma partition coefficients used in physiological pharmacokinetic models. J. Pharmacokin. Biopharm., 7:117-125.
47. Clark, L. H., Setzer, R. W., and Barton, H. A. (2004): Framework for evaluation of physiological-based pharma-cokinetic models for use in safety or risk assessment. Risk Anal, 24:1697-1717.
48. Clarke, D. O. et al. (1992): 2-Methoxyacetic acid dosim-etry-teratology relationships in CD-1 mice exposed to 2-methoxyethanol. Toxicol. Appl. Pharmacol., 114:77-87.
49. Clarke, D. O. et al. (1993): Pharmacokinetics of 2-methoxyethanol and 2-methoxyacetic acid in the pregnant mouse: a physiologically based mathematical model. Toxicol. Appl. Pharmacol., 121:239-252.
50. Clewell, H. J., III, and Andersen, M. E. (1987): Dose, species and route extrapolation using physiologically based pharmacokinetic models. Drinking Water and Health, 8:159-182.
51. Clewell, H. J., III, and Andersen, M. E. (1994): Physiologically based pharmacokinetic modeling and bioactiva-tion of xenobiotics. Toxicol. Indust. Health, 10:1-24.
52. Clewell, H. J., III, Andersen, M. E., and Barton, H. A. (2002): A consistent approach for the application of phar-macokinetic modeling in cancer and noncancer risk assessment. Environ. Health Perspect., 110:85-93.
53. Clewell, H. J., III, Gearhart, J. M., Gentry, P. R., Covington, T. R., Van Landingham, C. B., Crump, K. S., and Shipp, A. M. (1999): Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal., 19:547-558.
54. Clewell, H. J., III, Gentry, P. R., Covington, T. R., Sarangapani, R., and Teeguarden, J. G. (2004): Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci., 79:381-393.
55. Clewell, H. J., III, Gentry, P. R., and Gearhart, J. M. (1997): Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment. Toxicol. Environ. Health, 52:475-515.
56. Clewell, H. J., III, Gentry, P. R., Gearhart, J. M., Covington, T. R., Banton, M. I., and Andersen, M. E. (2001): Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicol. Sci., 63:160-172.
57. Clewell, H. J., III, Gentry, P. R., Kester, J. E., and Andersen, M. E. (2005): Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene. Crit. Rev. Toxicol., 35:413-433.
58. Clewell, H. J., III, and Jarnot, B. M. (1994): Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. Risk Anal., 14:265-276.
59. Clewell, H. J., III, Lee, T. S., and Carpenter, R. L. (1994): Sensitivity of physiologically based pharmacokinetic models to variation in model parameters-methylene chloride. Risk Anal., 14:521-531.
60. Clewell, R. A., and Gearhart, J. M. (2002): Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure. Environ. Health Per-spect., 110:A333-A337.
61. Clewell, R. A., Merrill, E. A., Yu, K. O., Mahle, D. A., Sterner, T. R., Fisher, J. W., and Gearhart, J. M. (2003): Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically based pharmacokinetic modeling. Toxicol. Sci., 74:416-436.
62. Clewell, R. A., Merrill, E. A., Yu, K. O., Mahle, D. A., Sterner, T. R., Mattie, D. R., Robinson, P. J., Fisher, J. W., and Gearhart, J. M. (2003): Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: a physiologically based pharmacokinetic analysis of perchlo-rate and iodide kinetics in the rat. Toxicol. Sci., 73:235-255.
63. Cohn, M. S. (1987): Sensitivity analysis in pharmacoki-netic modeling. Drinking Water Health, 8:265-272.
64. Collins, J. M., Dedrick, R. L., Flessner, M. F., and Guarino, A. M. (1982): Concentration dependent disappearance of fluorouracil from peritoneal fluid in the rat: experimental observations and distributing modeling. J. Pharm. Sci., 71:735-738.
65. Conolly, R. B., and Andersen, M. E. (1991): Biologically based pharmacodynamic models: tools for toxicological research and risk assessment. Annu. Rev. Toxicol. Pharmacol., 31:503-523.
66. Corley, R. A., Markham, D. A., Banks, C., Delorme, P., Masterman, A., and Houle, J. M. (1997): Physiologically based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapor by humans. Fundam. Appl. Toxicol., 39:120-130.
67. Corley, R. A., Mast, T. J., Carney, E. W., Rogers, J. M., and Daston, G. P. (2003): Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit. Rev. Toxicol, 33:137-211.
68. Csanady, G. A., and Filser, J. G. (2001): The relevance of physical activity for the kinetics of inhaled gaseous substances. Arch. Toxicol., 74:663-672.
69. Csanady, G. A., Kreuzer, P. E., Baur, C., and Filser, J. G., (1996): A physiological toxicokinetic model for 1,3-buta-diene in rodents and man: blood concentrations of 1,3-butadiene, its metabolically formed epoxides, and of haemoglobin adducts-relevance of glutathione depletion. Toxicology, 113:300-305.
70. Dallas, C. E., Bruckner, J. V., Megden, J. L., and Weir, F. W. (1986): A method for direct measurements of systemic uptake and elimination of volatile organics in small mammals. J. Pharmacol. Meth., 16:239-250.
71. Dallas, C. E., Chen, X. M., O'Bass, K., Muralidhara, S., Varkonyi, P., and Bruckner, J. (1994): Development of a physiologically based pharmacokinetic model for perchloroethylene using tissue concentration-time data. Toxicol. Appl. Pharmacol., 128:50-59.
72. Davies, B., and Morris, T. (1993): Physiological parameters in laboratory animals and humans. Pharm. Res., 10:1093-1095.
73. Dedrick, R. L., Forrester, D. D., and Ho, D. H. W. (1972): In vitro/in vivo correlation of drug metabolism: deamination of 1-β-D-arabinosyl cytosine. Biochem. Pharmacol., 21:1-16.
74. Dedrick, R. L., Zaharko, D. S., and Lutz, R. J. (1973): Transport and binding of methotrexate in vivo. J. Pharm. Sci., 62:882-890.
75. DeJongh, J., and Blaauboer, B. J. (1996): In vitro-based and in vivo-based simulations of benzene uptake and metabolism in rats. ATLA, 24:179-190.
76. DeJongh, J., and Blaauboer, B. J. (1997): Simulation of lindane kinetics in rats. Toxicology, 122:1-9.
77. DeJongh, J., and Blaauboer, B. J. (1996): Simulations of toluene kinetics in the rat by a physiologically based phar-macokinetic model with application of biotransformation parameters derived independently in vitro and in vivo. Fundam. Appl. Toxicol., 32:260-268.
78. DeJongh, J., and Blaauboer, B. J. (1997): Evaluation of in vitro-based simulations of toluene uptake and metabolism in rats. Toxicol. In Vitro, 11:485-489.
79. DeJongh, J., Verhaar, H. J. M., and Hermens, J. L. M. (1997): A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch. Toxicol., 72:17-25.
80. Delp, M. D., Manning, R. O., Bruckner, J. V., and Armstrong, R. B. (1991): Distribution of cardiac output during diurnal changes of activity in rats. Am. J. Physiol., 261:H1487-1493.
81. Dennison, J. E., Andersen, M. E., and Yang, R. S. H. (2003): Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. Inhal. Toxicol., 15:961-986.
82. Dennison, J. E., Andersen, M. E., and Yang, R. S. H. (2005): Pitfalls and related improvements of in vivo gas uptake pharmacokinetic experimental systems. Inhal. Tox-icol, 17:539-548.
83. Dietz, K. F., Rodriguez-Giaxola, M., Traiger, G. J., Stella, V. J., and Himmelstein, K. J. (1981): Pharmacokinetics of 2-butanol and its metabolites in the rat. J. Pharmacokin. Biopharm., 9:553-573.
84. Dobrev, I. D., Andersen, M. E., and Yang, R. S. (2001): Assessing interactions thresholds for trichloroethylene in combination with tetrachloroethylene and 1,1,1-trichloro-ethane using gas uptake studies and PBPK modeling. Arch. Toxicol., 75:134-144.
85. Domenech, R. J., Hoffman, J. E., Noble, M. M., Saunder, K. B., Hensen, J. R., and Subijanto, S. (1996): Total and regional coronary blood flow measured by radioactive microsphere in conscious and anesthetized dogs. Circul. Res., 25:581-596.
86. Dong, M. H. (1994): Microcomputer programs for physiologically based pharmacokinetic (PB-PK) modeling. Comput. Methods Programs Biomed., 45:213-221.
87. D'Souza, R. W., Franci, W. R., and Andersen, M. W. (1988): Physiological model for tissue glutathione depletion and decreased resynthesis after ethylene dichloride exposures. J. Pharmacol. Exp. Ther., 245:563-568.
88. Easterling, M. R., Evans, M. V., and Kenyon, E. M. (2000): Comparative analysis of software for physiologically based pharmacokinetic modeling: simulation, optimization, and sensitivity analysis. Toxicol. Methods, 10:203-229.
89. El-Masri, H. A., Bell, D. A., and Portier, C. J. (1999): Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans. Toxicol. Appl. Pharmacol., 158:221-230.
90. El-Masri, H. A., and Portier, C. J. (1998): Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats and mice. Drug Metab. Dispos., 26:585-594.
91. Emond, C., Birnbaum, L. S., and DeVito, M. J. (2004): Physiologically based pharmacokinetic model for developmental exposures to TCDD in the rat. Toxicol. Sci., 80:115-133.
92. Emond, C., Charbonneau, M., and Krishnan, K. (2005): Physiologically based modeling of the accumulation in plasma and tissue lipids of a mixture of PCB congeners in female Sprague-Dawley rats. J. Toxicol. Environ. Health, 68:1393-1412.
93. Emond, C., and Krishnan, K. (2006): A physiological pharmacokinetic model based on tissue lipid content for simulating inhalation pharmacokinetics of highly lipo-philic volatile organic chemicals. Toxicol. Mech. Methods, 16(8):395-403.
94. Evans, M. V., and Andersen, M. E. (1995): Sensitivity analysis and the design of gas uptake inhalation studies. Inhal. Toxicol., 7:1075-1094.
95. Evans, M. V., and Andersen, M. E. (2000): Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlo-rodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicol. Sci., 54:71-80.
96. Falk, A., Gullstrand, E., Löf, A., and Wigaeus-Hjelm, E. (1990): Liquid/air partition coefficients of four terpenes. Br. J. Indust. Med., 47:62-64.
97. Farrar, D., Allen, B., Crump, K., and Shipp, A. (1989): Evaluation of uncertainty in input parameters to phar-macokinetic models and the resulting uncertainty in output. Toxicol. Lett., 49:371-385.
98. Farris, F. F., Dedrick, R. L., and King, F. G. (1988): Cisplatin pharmacokinetics: applications of a physiological model. Toxicol. Lett., 43:117-137.
99. Filser, J. G., and Bolt, H. M. (1979): Pharmacokinetics of halogenated ethylenes in rats. Arch. Toxicol., 42:123-136.
100. Filser, J. G., Kessler, W., and Csanady, G. A. (2004): The "Tuebingen dessicator" system, a tool to study oxidative stress in vivo and inhalation toxicokinetics. Drug Metab. Rev., 36:787-803.
101. Fiserova-Bergerova, V. (1975): Mathematical modeling of inhalation exposure. J. Combust. Toxicol., 32:201-210.
102. Fiserova-Bergerova, V. (1985): Toxicokinetics of organic solvents. Scand. J. Work Environ Health, 11(Suppl. 1-7):7-12.
103. Fiserova-Bergerova, V., and Diaz, M. L. (1986): Determination and prediction of tissue-gas partition coefficients. Int. Arch. Occup. Environ. Health, 58:75-87.
104. Fisher, J. W., Dorman, D. C., Medinsky, M. A., Welsch, F., and Conolly, R. B. (2000): Analysis of respiratory exchange of methanol in the lung of the monkey using a physiological model. Toxicol. Sci., 53:185-193.
105. Fisher, J., Mahle, D., Bankston, L., Greene, R., and Gearhart, J. (1997): Lactational transfer of volatile chemicals in breast milk. Indust. Hyg. Assoc. J., 58:425-431.
106. Fisher, J. W., Mahle, D., and Abbas, R. (1998): A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. Toxicol. Appl. Pharmacol., 152:339-359.
107. Fisher, J. W., Whittaker, T. A., Taylor, D. H., Clewell, H. J., and Andersen, M. E. (1989): Physiologically based pharmacokinetic modeling of the pregnant rat: multiroute exposure model for trichloroethylene and trichloroacetic acid. Toxicol. Appl Pharmacol., 99:395-414.
108. Frederick, C. B., Bush, M. L., Lomax, L. M., Black, K. A., Finch, L., Kimbell, J. S., Morgan, K. T., Subramaniam, R. P., Morris, J. B., and Ultman, J. S. (1998): Application of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper airways. Toxicol. Appl. Pharmacol., 152:211-231.
109. Frederick, C. B., Potter, D. W., Chang-Mateu, M. I., and Andersen, M. E. (1992): A physiologically based pharma-cokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. Toxicol. Appl. Pharmacol., 114:246-260.
110. Gabrielsson, J. L., Paalkow, L. K., and Nordstrom, L. (1987): A physiologically based pharmacokinetic model for theophylline disposition in the pregnant and nonpreg-nant rat. J. Pharmacokin. Biopharm., 12:149-165.
111. Gallo, J. M., Lam, F. C., and Perrier, D. G. (1987): Area method for the estimation of partition coefficients for physiological pharmacokinetic models. J. Pharmacokin. Biop-harm., 15:271-280.
112. Gargas, M. L. (1990): An exhaled breath chamber system for assessing rates of metabolism and rates of gastrointestinal absorption with volatile chemicals. J. Am. Coll. Toxicol., 9:447-453.
113. Gargas, M. L., and Andersen, M. E. (1989): Determining the kinetic constants of chlorinated ethane metabolism in the rat from rates of exhalation. Toxicol. Appl. Pharmacol., 99:344-353.
114. Gargas, M. L., Andersen, M. E., and Clewell, H. J. (1986): A physiologically based simulation approach for determining metabolic rate constants from gas uptake data. Toxicol. Appl. Pharmacol., 86:341-352.
115. Gargas, M. L., Burgess, R. J., Voisard, D. E. Cason, G. H., and Andersen, M. E. (1989): Partition coefficients of low molecular weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol., 98:87-99.
116. Gargas, M. L., Clewell, H. J., and Andersen, M. E. 1986): Gas uptake inhalation techniques and the rates of metabolism of chloromethanes, chloroethanes, and chloroethylenes in the rat. Inhal. Toxicol., 2:319.
117. Gargas, M. L., Clewell, H. J., and Andersen, M. E. (1986): Metabolism of inhaled dihalomethanes in vivo: differentiation of kinetic constants for two independent pathways. Toxicol. Appl. Pharmacol., 87:211-223.
118. Gargas, M. L., Seybold, P. G., and Andersen, M. E. (1988): Modeling the tissue solubilities and metabolic rate constants of halogenated methanes, ethanes and ethylenes. Toxicol. Lett., 43:235-256.
119. Gargas, M. L., Tyler, T. R., Sweeney, L. M., Corley, R. A., Weitz, K. K., Mast, T. J., Paustenbach, D. J., and Hays, S. M. (2000): A toxicokinetic study of inhaled ethylene glycol ethyl ether acetate and validation of physiologically based pharmacokinetic model for rat and human. Toxicol. Appl. Pharmacol., 165:63-73.
120. Gargas, M. L., Tyler, T. R., Sweeney, L. M., Corley, R. A., Weitz, K. K., Mast, T. J., Paustenbach, D. J., and Hays, S. M. (2000): A toxicokinetic study of inhaled ethylene glycol monomethyl ether (2-ME) and validation of a physiologically based pharmacokinetic model for the pregnant rat and human. Toxicol. Appl. Pharmacol., 165:53-62.
121. Gear, C. W. (1971): Numerical Initial Value Problems in Ordinary Differential Equations. Prentice-Hall, Engle-woods Cliffs, NJ.
122. Gearhart, J. M., Clewell, H. J. I., Crump, K. S., Shipp, A. M., and Silvers, A. (1995): Pharmacokinetic dose estimates of mercury in children and dose-response curves of performance tests in a large epidemiology study. Water Air Soil Pollut., 80:49-58.
123. Gearhart, J. M., Jepson, G. W., Clewell, H. J., Andersen, M. E., and Conolly, R. B. (1990): A physiologically based model for the in vivo inhibition of acetylcholinesterase by diisopropylfluorophosphate. Toxicol. Appl. Pharmacol., 16:295-310.
124. Gelman, A., Bois, F., and Jiang, J. (1996): Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J. Am. Stat. Assoc., 91:436.
125. Gentry, P. R., Covington, T. R., Andersen, M. E., and Clewell, H. J., III. (2002): Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul. Toxicol. Pharmacol., 36:51-68.
126. Gentry, P. R., Haber, L. T., McDonald, T. B., Zhao, Q., Covington, T., Nance, P., Clewell, H. J., III, and Lipscomb, J. C. (2004): Data for physiologically based pharmacokinetic modeling in neonatal animals: physiological parameters in mice and Sprague-Dawley rats. J. Child Health, 2:363-411.
127. Gerde, P., and Dahl, A. R. (1991): A model for the uptake of inhaled vapors in the nose of the dog during cyclic breathing. Toxicol. Appl. Pharmacol., 109:276-288.
128. Gibaldi, M., and Perrier, D. (1982): Pharmacokinetics. Marcel Dekker, New York.
129. Haber, L. T., Maier, A., Gentry, P. R., Clewell, H. J., and Dourson, M. L. (2002): Genetic polymorphisms in assessing interindividual variability in delivered dose. Regul. Toxicol. Pharmacol., 35:177-197.
130. Haddad, S., Béliveau, M., Tardif, R., and Krishnan, K. (2001): A PBPK modeling approach to account for interactions in the health risk assessment of chemical mixtures. Toxicol. Sci., 63:125-131.
131. Haddad, S., Gad, S. C., Tardif, R., and Krishnan, K. (1995): Statistical approaches for the validation of physiologically based pharmacokinetic (PBPK) models. Toxicologist, 15:258.
132. Haddad, S., Pelekis, M., and Krishnan, K. (1996): A methodology for solving physiologically based pharmacoki-netic models without the use of simulation softwares. Toxicol. Lett., 85:113-126.
133. Haddad, S., Poulin, P., and Krishnan, K. (2000): Ratio of lipid content in adipose tissues and blood as the sole determinant of the adipose tissue-blood partition coefficients of highly lipophilic organic chemicals. Chemosphere, 40:839-843.
134. Haddad, S., Tardif, R., Charest-Tardif, G., and Krishnan, K. (2000): Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. Toxicol. Appl. Pharmacol., 167:199-209.
135. Haddad, S., Withey, J., Laparé, S., Law, F. C. P., and Krishnan, K. (1998): Physiologically based pharmacoki-netic modeling of pyrene in the rat. Environ. Toxcol. Pharmacol., 5:245-255.
136. Haggard, H. W. (1924): The absorption, distribution and elimination of ethyl ether: analysis of the mechanism of the absorption and elimination of such a gas or vapor as ethyl ether. J. Biol. Chem., 59:753-770.
137. Hattis, D., White, P., Marmorstein, L., and Koch, P. (1990): Uncertainties in pharmacokinetics modeling for perchlo-roethylene. I. Comparison of model structure, parameters, and predictions for low dose metabolic rates for models by different authors. Risk Anal., 10:449-458.
138. Hetrick, D. M., Jarabek, A. M., and Travis, C. C. (1991): Sensitivity analysis for physiologically based pharmacok-inetic models. J. Pharmacokin, Biopharm., 19:1-20.
139. Hilderbrand, R. L., Andersen, M. E., and Jensen, L. J. (1981): Prediction of in vivo kinetic constants for metabolism of inhaled vapors from kinetic constants measured in vitro. Fundam. Appl. Toxicol., 1:403-409.
140. Himmelstein, M. W., Carpenter, S. C., Evans, M. V., Hinderliter, P. M., and Kenyon, E. M. (2004): Kinetic modeling of beta-chloroprene metabolism. II. The applications of physiologically based modeling for cancer dose response analysis. Toxicol. Sci., 79:28-37.
141. Hoang, K. C. T. (1995): Physiologically based pharmaco-kinetic models: mathematical fundamentals and simulation implementations. Toxicol. Lett., 79:87-98.
142. Igari, Y., Sugiyama, Y., Sawada, Y., Iga, Y., and Hanano, M. (1983): Prediction of diazepam disposition in rat and man by a physiologically based pharmacokinetic model. J. Pharmacokin. Biopharm., 11:577-593.
143. Iman, R., and Helton, J. (1998): An investigation of uncertainty and sensitivity analysis techniques for computer models. Risk Anal., 8:71-90.
144. International Commission on Radiation Protection (1975): Report of the Task Group on Reference Man, ICRP Publication No. 23. Pergamon Press, New York.
145. Isukapalli, S. S., Roy, A., and Georgopoulos, P. G. (1998): Stochastic response surface methods (SRSMs) for uncertainty propagation: applications to environmental and biological systems. Risk Anal., 18:351-363.
146. Iwatsubo, T., Suzuki, H., and Sugiyama, Y. (1997): Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J. Pharmacol. Exp. Ther., 283:462-469.
147. Iyengar, S., and Rao, M. S. (1983): Statistical techniques in modeling of complex systems: single versus multiresponse models. IEEE Trans. Syst. Man. Cybernet., 13:175-189.
148. Jain, R. K., Gerlowski, L. E., Weissbrod, J. M., Wang, J., and Pierson, R. N. (1982): Kinetics of uptake, distribution and excretion zinc in rats. Ann. Biomed. Eng., 9:347-361.
149. Jang, J. Y., Droz, P. O., and Kim, S. (2001): Biological monitoring of workers exposed to ethylbenzene and co-exposed to xylene. Int. Arch. Occup. Environ. Health, 74:31-37.
150. Johanson, G. (1991): Modeling of respiratory exchange of polar solvents. Ann. Occup. Hyg., 35:323-339.
151. Johanson, G., and Dynesius, B. (1988): Liquid: air partition coefficients for six commonly used glycol ethers. Br. J. Indust. Med., 45:561-564.
152. Johanson, G., and Filser, J. G. (1992): Experimental data from closed chamber gas uptake studies in rodents suggest lower uptake rate of chemical than calculated from literature values on alveolar ventilation. Arch. Toxicol., 66:291-295.
153. Johanson, G., Jonsson, F., and Bois, F. (1999): Development of new technique for risk assessment using physiologically based pharmacokinetic models. Am. J. Indust. Med., 36(Suppl. 1):101-103.
154. Johanson, G., and Naslund, P. H. (1988): Spreadsheet programming: a new approach in physiologically based modeling of solvent toxicokinetics. Toxicol. Lett., 41:115-127.
155. Jonsson, F., Bois, F., and Johanson, G. (2001): Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol. Sci., 59:209-218.
156. Jonsson, F., Bois, F. Y., and Johanson, G. (2001): Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects. Arch. Toxicol., 75:189-199.
157. Jonsson, F., and Johanson, G. (2001): A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicol. Appl. Pharmacol., 174:99-112.
158. Jonsson, F., and Johanson, G. (2001): Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology, 157:177-193.
159. Jonsson, F., and Johanson, G. (2002): Physiologically based modeling of the inhalation kinetics of styrene in humans using a Bayesian population approach. Toxcol. Appl. Pharmacol., 179:35-49.
160. Jonsson, F., and Johanson, G. (2003): The Bayesian population approach to physiological toxicokinetic-toxicody-namic models: an example using the MCSim software. Toxicol. Lett., 138:143-150.
161. Karba, R., Zupancic, B., and Bremsak, F. (1990): Simulation tools in pharmacokinetic modeling. Acta Pharm. Jugosl., 40:247-262.
162. Kedderis. L. B., Mills, J. J., Andersen, M. E., and Birnbaum, L. S. (1993): A physiologically based pharmacokinetic model of 2,3,7,8-tetrabromodibenzo-p-dioxin (TBDD) in the rat: tissue distribution and CYPIA induction. Toxicol. Appl. Pharmacol., 121:87-98.
163. Kety, S. S. (1951): The theory and application of the exchange of inert gas at the lungs. Pharmacol. Rev., 3:1-41.
164. Keys, D. A., Bruckner, J. V., Muralidhara, S., and Fisher, J. W. (2003): Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmaco-kinetic models for trichloroethylene. Toxicol. Sci., 76:35-50.
165. Keys, D. A., Wallace, D. G., Kepler, T. B., and Conolly, R. B., (2000): Quantitative evaluation of alternative mechanisms of blood disposition of di(n-butyl) phthalate and mono(n-butyl) phthalate in rats. Toxicol. Sci., 53:173-184.
166. Khor, S. P., and Mayersohn, M. (1991): Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling: residual tissue blood. I. Theoretical considerations. Drug Metab. Disp., 19:478-485.
167. Kootsey, J. M., Kohn, M. C., Feezor, M. D., Mitchell, G. R., and Fletcher, P. R. (1986): ScoP: an interactive simulation control program for micro- and minicomputers. Bull. Math. Biol., 48:427-441.
168. Krewski, D., Wang, Y., Barlett, S., and Krishnan, K. (1995): Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models. J. Biopharm. Statist., 5:245-271.
169. Krishnan, K., and Andersen, M. E. (2001): Physiologically based pharmacokinetic modeling in toxicology. In: Principles and Methods of Toxicology, edited by A. W. Hayes, Taylor & Francis, New York, pp. 193-241.
170. Krishnan, K., Gargas, M. L., and Andersen, M. E. (1993): In vitro toxicology and risk assessment. Altern. Meth. Toxicol., 9:185-203.
171. Krishnan, K., Gargas, M. L., Fennell, T. R., and Andersen, M. E. (1992): A physiologically based description of ethylene oxide dosimetry in the rat. Toxicol. Indust. Health, 8:121-140.
172. Krishnan, K., Haddad, S., Beliveau, M., and Tardif, R. (2002): Physiological modeling and extrapolation of phar-macokinetic interactions from binary to more complex chemical mixtures. Environ. Health Perspect., 110(Suppl. 6):989-994.
173. Krishnan, K., and Johanson, G. (2005): Physiologically based pharmacokinetic and toxicokinetic models in cancer risk assessment. J. Environ. Sci. Health, 23(C):31-53.
174. Krishnan, K., Pelekis, M. L., and Haddad, S. (1995): A simple index for describing the discrepancy between PBPK model simulations and experimental data. J. Toxicol. Indust. Health, 11:413-421.
175. Labaune, J. P. (1988): Pharmacocinétique: principes fondamentaux. Masson, Paris.
176. Lam, G., Chen, M. L., and Chiou, W. L. (1982): Determination of tissue- blood partition coefficients in physiologically based pharmacokinetic models. J. Pharm. Sci., 71:454-456.
177. Licata, A. C., Dekant, W., Smith, C. E., and Borghoff, S. J. (2001): A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses. Toxicol. Sci., 62: 191-204.
178. Lin, J. H., Sugiyama, Y., Awazu, S., and Hanano, M. (1982): In vitro and in vivo evaluation of the tissue to blood partition coefficients for physiological pharmacokinetic models. J. Pharmacokin. Biopharm., 10:637-647.
179. Lin, J. H., Sugiyama, Y., Awazu, S., and Hanano, M. (1982): Physiological pharmacokinetics of ethoxyben-zamine based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokin. Biopharm., 10:649-661.
180. Lipscomb, J. C., Barton, H. A., Tornero-Velez, R., Evans, M. V., Alcasey, S., Snawder, J. E., and Laskey, J. (2004): The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J. Toxicol. Environ. Health, 67(A):537-553.
181. Lipscomb, J. C., Fisher, J. W., Confer, P. D., and Bycz-kowski, J. Z. (1998): In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. Toxicol. Appl. Pharmacol., 152:376-387.
182. Lipscomb, J. C., and Ohanian, E. V., Eds. (2007): Toxicokinetics and Risk Assessment. Informa Health Care, New York.
183. Lipscomb, J. C., Teuschler, L. K., Swartout, J., Popken, D., Cox, T., and Kedderis, G. L. (2003): The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk. Anal., 6:1221-1238.
184. Loizou, G. D., Eldirdiri, N. I., and King, L. J. (1996): Physiologically based pharmacokinetics of uptake by inhalation of a series of 1,1,1-trihaleothanes: correlation with various physicochemical parameters. Inhal. Toxicol., 8:1-19.
185. Mapleson, W. W. (1963): An electric analog for uptake and elimination in man. J. Appl. Physiol., 18:197-204.
186. Maruyama, W., Yoshida, K., Tanaka, T., and Nakanishi, J. (2002): Determination of tissue-blood partition coefficients for a physiological model for humans, and estimation of dioxin concentration in tissues. Chemosphere, 46:975-985.
187. Maruyama, W., Yoshida, K., Tanaka, T., and Nakanishi, J. (2003): Simulation of dioxin accumulation in human tissues and analysis of reproductive risk. Chemosphere, 53:301-313.
188. Mauderly, J. L. (1990): Measurement of respiration and respiratory responses during inhalation exposures. J. Am. Coll. Toxicol., 9:397-406.
189. McDougal, J. N., Jepson, G. W., Clewell, H. J., and Andersen, M. E. (1985): Dermal absorption of dihalomethane vapors. Toxicol. Appl. Pharmacol., 79:150-158.
190. McDougal, J. N., Jepson, G. W., Clewell, H. J., MacNaugh-ton, M. G., and Andersen, M. E. (1986): A physiological pharmacokinetic model for dermal absorption of vapors in the rat. Toxicol. Appl. Pharmacol., 85:286-294.
191. Meek, M. E., Beauchamp, R., Long, G., Turner, L., and Walker, M. (2002): Chloroform: exposure estimation, hazard characterisation, and exposure-response analysis. J. Toxicol. Environ. Health, 5(B):283-334.
192. Menzel, D. B., Wolpert, R. L., Boger, J. R., and Kootsey, J. M. (1987): Resources available for simulation in toxicology: specialized computers, generalized software and communication networks. Drinking Water and Health, 8:229-254.
193. Merrill, E. A., Clewell, R. A., Gearhart, J. M., Robinson, P. J., Sterner, T. R., Yu, K. O., Mattie, D. R., and Fisher, J. W. (2003): PBPK predictions of perchlorate distribution and its effect of thyroid uptake of radioiodide in the male rat. Toxicol. Sci., 73:256-269.
194. Merrill, E. A., Clewell, R. A., Robinson, P. J., Jarabek, A. M., Gearhart, J. M., Sterner, T. R., and Fisher, J. W. (2005): PBPK model for radioactive iodide and perchlorate kinetics and perchlorate-induced inhibition of iodide uptake in humans. Toxicol. Sci., 83:25-43.
195. Meulenberg, C. J., and Vijverberg, H. P. (2000): Empirical relations predicting human and rat tissue-air partition coefficient of volatile organic compounds. Toxicol. Appl. Pharmacol., 165:206-216.
196. Miller, F. J., Overton, J. H., Jaskot, R. H., and Menzel, D. B. (1985): A model for the regional uptake of gaseous pollutants in the lung. I. The sensitivity of the uptake of ozone in the human lung to lower respiratory tract secretions and exercise. Toxicol. Appl. Pharmacol., 79:11-27.
197. Mork, A. K., and Johanson, G. (2006): A human physiological model describing acetone kinetics in blood and breath during various levels of physical exercise. Toxicol. Lett, 164:6-15.
198. Mortensen, B., Lokken, T., Zahlsen, K., and Nilsen, O. G. (1997): Comparisons and in vivo relevance of two different in vitro headspace metabolic systems: liver S9 and liver slices. Pharmacol. Toxicol., 81:35-41.
199. Mortensen, B., and Nilsen, O. G. (1988): Allometric species comparison of toluene and n-hexane metabolism: prediction of hepatic clearance in man from experiments with rodent liver S9 in headspace vial equilibration system. Pharmacol. Toxicol., 82:183-188.
200. Nakajima, T., and Sato, A. (1979): Enhanced activity of liver drug-metabolizing enzymes for aromatic and chlorinated hydrocarbons following food deprivation. Toxicol. Appl. Pharmacol., 50:549-556.
201. National Toxicology Program (1985): NTP Technical Report on the Toxicology and Carcinogenesis Studies of Dichloromethane in Fisher-344 Rats and B6C3F¡ Mice (Inhalation Studies), NTP Tech. Rep. No. 306. National Toxicology Program, Washington, D.C.
202. Nestorov, I. A. (2001): Modeling and simulation of variability and uncertainty in toxicokinetics and pharmacoki-netics. Toxicol. Lett., 120:411-420.
203. Nichols, J., Rheingans, P., Lothenbach, D., McGeachie, R., Skow, L., and McKim, J. (1994) Three-dimensional visualization of physiologically based kinetic model outputs. Environ. Health Perspect., 102:952-956.
204. Nong, A., McCarver, D. G., Hines, R. N., and Krishnan, K. (2005): Modeling interchild differences in pharmacok-inetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol., 214(1):78-87.
205. O'Flaherty, E. (1998): Physiologically based models of metal kinetics. CRC Crit. Rev. Toxicol., 28(3):271-317.
206. O'Flaherty, E. J. (1981): Toxicants and Drugs: Kinetics and Dynamics. John Wiley & Sons, New York.
207. O'Flaherty, E. J., Scott, W., Schreiner, C., and Beliles, R. P. (1992): A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid. Toxicol. Appl. Pharmacol., 112:245-256.
208. Overton, J. H., Graham, R. C., and Miller, F. J. (1987): Mathematical modeling of ozone absorption in the lower respiratory tract. Drinking Water Health, 8:302-311.
209. Page, N. P., Singh, D. V., Farland, W., Goodman, J. I., Conolly, R. B., Andersen, M. E., Clewell, H. J., Frederick, C. B., Yamasaki, H., and Lucier, G. (1997): Implementation of EPA revised cancer assessment guidelines: incorporation of mechanistic and pharmacokinetic data. Fundam. Appl. Toxicol., 37:16-36.
210. Parham, F. M., Kohn, M. C., Matthews, H. B., DeRosa, C., and Portier, C. J. (1997): Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. I. Tissue:blood partition coefficients. Toxicol. Appl. Pharmacol., 144:340-347.
211. Parham, F. M., and Portier, C. J. (1998): Using structural information to create physiologically based pharmacoki-netic models for all polychlorinated biphenyls. II. Rates of metabolism. Toxicol. Appl. Pharmacol., 151:110-116.
212. Paterson, S., and MacKay, D. (1989): Correlation of tissue, blood, and air partition coefficients of volatile organic chemicals. Br. J. Indust. Med., 46:321-328.
213. Payne, M. P., and Kenny, L. C. (2002): Comparison of models for the estimate of biological partition coefficients. J. Toxicol. Environ. Health, 65(Part A):897-931.
214. Pelekis, M., Krewski, D., and Krishnan, K. (1997): Physiologically based algebraic expressions for predicting steady-state toxicokinetics of inhaled vapors. Toxicol. Meth., 7:205-225.
215. Pelekis, M., Poulin, P., and Krishnan, K. (1995): An approach for incorporating tissue composition data into physiologically based pharmacokinetic models. Toxicol. Indust. Health, 11:511-522.
216. Poet, T. S., Kousba, A. A., Dennison, S. L., and Timchalk, C. (2004): Physiologically based pharmacokinetic/phar-macodynamic model for the organophosphorus pesticide diazinon. Neurotoxicology, 25:1013-1030.
217. Poet, T. S., Weitz, K. K., Gies, R. A., Edwards, J. A., Thrall, K. D., Corley, R. A., Tanojo, H., Hui, X., Maibach, H. I., and Wester, R. C. (2002): PBPK modeling of the percutaneous absorption of perchloroethylene from a soil matrix in rats and humans. Toxicol. Sci., 67:17-31.
218. Poet, T. S., Wu, H., English, J. C., and Corley, R. A. (2004): Metabolic rate constants for hydroquinone in F344 rat and human liver isolated hepatocytes: application to a PBPK model. Toxicol. Sci., 82:9-25.
219. Portier, C. J., and Kaplan, N. L. (1989): Variability of safe estimated when using complicated models of carcinogenic processes. A dose study: methylene chloride. Fundam. Appl. Toxicol., 13:533-544.
220. Poulin, P., Beliveau, M., and Krishnan, K. (1999): Mechanistic animal replacement approaches for predicting phar-macokinetics of organic chemicals. In: Toxicity Assessment Alternatives: Methods, Issues, Opportunities, edited by H. Salem and S. A. Katz. Humana Press, Totowa, NJ, pp. 115-139.
221. Poulin, P., and Krishnan, K. (1995): An algorithm for predicting tissue-blood partition coefficients of organic chemicals from n-octanol:water partition coefficient data. J. Toxicol. Environ. Health, 46:117-129.
222. Poulin, P., and Krishnan, K. (1995): A biologically based algorithm for predicting human tissue-blood partition coefficients of organic chemicals. Human Exp. Toxicol., 14:273-280.
223. Poulin, P., and Krishnan, K. (1996): A mechanistic algorithm for predicting blood-air partition coefficients of organic chemicals with the consideration of reversible binding in hemoglobin. Toxicol. Appl. Pharmacol., 136:131-137.
224. Poulin, P., and Krishnan, K. (1996): A tissue composition-based algorithm for predicting tissue-air partition coefficients of organic chemicals. Toxicol. Appl. Pharmacol., 136:136-130.
225. Poulin, P., and Krishnan, K. (1996): Molecular structure-based prediction of the partition coefficients of organic chemicals for physiological pharmacokinetic models. Tox-icol. Meth., 6:117-137.
226. Poulin, P., and Krishnan, K. (1998): A quantitative struc-ture-toxicokinetic relationship model for highly metabolised chemicals. ATLA, 26:45-59.
227. Poulin, P., and Krishnan, K. (1999): Molecular structure-based prediction of the toxicokinetics of inhaled vapors in humans. Int. J. Toxicol., 18:7-18.
228. Price, K., Haddad, S., and Krishnan, K. (2003): Physiological modeling of age-specific changes in the pharmaco-kinetics of organic chemicals in children. J. Toxicol. Environ. Health, 66(A):417-433.
229. Price, P. S., Conolly, R. B., Chaisson, K., Gross, E. A., Young, J. S., Mathis, E. T., and Tedder, D. R. (2003): Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol., 33:469-503.
230. Ramsey, J. C., and Andersen, M. E. (1984): A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol., 73:159-175.
231. Reddy, M. B., Andersen, M. E., Morrow, P. E., Dobrev, I. D., Varaprath, S., Plotzke, K. P., and Utell, M. J. (2003): Physiological modeling of inhalation kinetics of octame-thylcyclotetrasiloxane in humans during rest and exercise. Toxicol. Sci., 72:3-18.
232. Reddy, M. B., Yang, R. S. H., Clewell, H. J., III, and Andersen, M. E. (2005): Physiologically Based Pharmacokinetic Modeling: Science and Application. John Wiley & Sons, New York, p. 420.
233. Reitz, R. H., Gargas, M. L., Andersen, M. E., Provan, W. M., and Green, T. L. (1996): Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacok-inetic model. Toxicol. Appl. Pharmacol., 137:253-267.
234. Reitz, R. H., Mandrela, A. L., and Guengerich, F. P. (1989): In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacoki-netic models. Toxicol. Appl. Pharmacol., 97:230-246.
235. Reitz, R. H., McCroskey, P. S., Park, C. N., Andersen, M. E., and Gargas, M. L. (1990): Development of a physiologically based pharmacokinetic model for risk assessment with 1,4-dioxane. Toxicol. Appl. Pharmacol., 105:37-54.
236. Reitz, R. H., Mendrala, A. L., Park, C. N., Andersen, M. E., and Guengerich, F. P. (1988): Incorporation of in vitro enzyme data into the physiologically based pharmacokinetic (PBPK) model for methylene chloride: implications for risk assessment. Toxicol. Lett., 43:97-116.
237. Rey, T. D., and Havranek, W. A. (1996): Some aspects of using the SimuSolv program for environmental, pharma-cokinetics and toxicological applications. Ecolog. Model., 86:277-282.
238. Rideout, V. C. (1991): Mathematical and Computer Modeling of Physiological Systems. Prentice Hall, New York.
239. Riggs, D. S. (1970): The Mathematical Approach to Physiological Problems: A Critical Treatise. MIT Press, Cambridge, MA.
240. Robinson, P. J. (1991): Effect of microcirculatory heterogeneity in the determination of pharmacokinetic parameters: implications for risk assessment. Drug Metab. Rev., 23:43-64.
241. Robinson, P. J. (1992): Physiologically based liver modeling and risk assessment. Risk Anal., 12:139-148.
242. Ross, R., Leger, L., Guardo, R., de Guise, J., and Pike, B. G. (1991): Adipose tissue volumes measured by magnetic resonance imaging and computerized tomography in rats. J. Appl. Physiol., 70:2164-2172.
243. Roth, R. A., and Vinegar, A. (1990): Action by the lungs on circulating xenobiotic agents with a case study of physiologically based pharmacokinetic modeling of benzo(a)pyrene disposition. Pharmacol. Therap., 48: 143-155.
244. Santostefano, M. J., Wang, X., Richardson, V. M., Ross, D. G., DeVito, M. J., and Birnbaum, L. S. (1998): A phar-macodynamic analysis of TCDD-induced cytochrome P450 gene expression in multiple tissues: dose- and timedependent effects. Toxicol. Appl. Pharmacol., 151: 294-310.
245. Sarangapani, R., Gentry, P. R., Covington, T. R., Teeguarden, J. G., and Clewell, H. J., III (2003): Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of the vapor. Toxicol. Sci., 15:987-1016.
246. Sarangapani, R., Teeguarden, J. G., Gentry, P. R., Clewell, H. J., III, Barton, H. A., and Bogdanffy, M. S. (2004): Interspecies dose extrapolation for inhaled dimethyl sulfate: a PBPK model-based analysis using nasal cavity N7-methylguanine adducts. Inhal. Toxicol., 16:593-605.
247. Sato, A., and Nakajima, T. (1997): A vial equilibration method to evaluate the drug metabolizing enzyme activity for volatile hydrocarbons. Toxicol. Appl. Pharmacol., 47:41-46.
248. Sato, A., and Nakajima, T. (1979): Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. Br. J. Indust. Med., 36:231-234.
249. Schoeffner, D. J., Warren, D. A., Muralidhara, S., Bruckner, J. V., and Simmons, J. E. (1999): Organ weights and fat volume in rats as a function of strain and age. J. Toxicol. Environ. Health, 56(Part A):449-462.
250. Shin, B. S., Kim, C. H., Jun, Y. S., Kim, D. H., Lee, B. M., Yoon, C. H., Park, E. H., Lee, K. C., Han, S. Y., Park, K. L., Kim, H. S., and Yoo, S. D. (2004): Physiologically based pharmacokinetics of bisphenol A. J. Toxicol. Environ. Health A, 67:1971-1985.
251. Singh, D. V., Spitzer, H. L., and White, P. D. (1987): Addendum to the Health Risk Assessment for Dichlo-romethane: Updated Carcinogenicity Assessment for Dichloromethane, EPA 600/8-82/004F. U.S. Environmental Protection Agency, Washington, D.C.
252. Slikker, Jr., W., Andersen, M. E., Bogdanffy, M. S., Bus, J. S., Cohen, S. D., Conolly, R. B., David, R. M., Doerrer, N. G., Dorman, D. C., Gaylor, D. W., Hattis, D., Rogers, J. M., Woodrow, Setzer, R., Swenberg, J. A., and Wallace, K. (2004): Dose-dependent transitions in mechanisms of toxicity. Toxicol. Appl. Pharmacol., 201:203-225.
253. Slob, W., Janssen, P. H. M., and Van den Hof, J. M. (1997): Structural identifiability of PBPK models: practical consequences for modeling strategies and study designs. Crit. Rev. Toxicol., 27(2):261-272.
254. Sultatos, L. G. (1990): A physiologically based pharma-cokinetic model for parathion based on chemical specific parameters determined in vitro. J. Am. Coll. Toxicol., 9:611-617.
255. Sultatos, L. G., Kim, B., and Woods, L. (1990): Evaluation of estimations in vitro of tissue-blood distribution coefficients for organothiophosphate insecticides. Toxicol. Appl. Pharmacol., 103:52-55.
256. Sweeney, L. M., Gargas, M. L., Strother, D. E., and Ked-deris, G. L. (2003): Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Toxicol. Sci., 71:27-40.
257. Sweeney, L. M., Tyler, T. R., Kirman, C. R., Corley, R. A., Reitz, R. H., Paustenbach, D. J., Holsen, J. F., Whorton, M. D., Thompson, K. M., and Gargas, M. L. (2001): Proposed occupational exposure limits for select ethylene glycol ethers using PBPK models and Monte Carlo simulations. Toxicol. Sci., 62:124-139.
258. Tardiff, R., Charest-Tardif, G., Brodeur, J., and Krishnan, K. (1997): Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicol. Appl. Pharmacol., 144:120-134.
259. Tardiff, R., Lapare, S., Charest-Tardif, G., Brodeur, J., and Krishnan, K. (1995): Physiologically based pharmacoki-netic modeling of a mixture of toluene and xylene in humans. Risk Anal., 15:335-342.
260. Teeguarden, J. G., Deisinger, P. J., Poet, T. S., English, J. C., Faber, W. D., Barton, H. A., Corley, R. A., and Clewell, H. J., III (2005): Derivation of a human equivalent concentration for n-butanol using a physiologically based pharmacokinetic model for n-butyl acetate and metabolites n-butanol and n-butyric acid. Toxic. Sci., 85:429-446.
261. Teeguarden, J. G., Waechter, J. M., Jr., Clewell, H. J., III, Covington, T. R., and Barton, H. A. (2005): Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. Toxicol. Sci., 85:823-838.
262. Teorell, T. (1937): Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch. Int. Pharmacodyn., 57:205-225.
263. Teorell, T. (1937): Kinetics of distribution of substances administered to the body. II. The intravascular modes of administration. Arch Int. Pharmacodyn., 57:226-240.
264. Terasaki, T., Iga, T., Sugiyama, Y., Sawada, Y., and Hanano, M. (1984): Nuclear binding as a determinant of tissue distribution of adriomycin, daunomycin, adramycinol, daunorubi-cinol and actinomycin D. J. Pharmacodyn., 7:269-277.
265. Thomas, R. S., Bigelow, P. L., Keefe, T. J., and Yang, R. S. H. (1996): Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. Am. Indust. Hyg. Assoc. J., 57:23-32.
266. Thompson, C., Sonawane, B., Nong, A., and Krishnan, K. (2007): Considerations for applying physiologically based pharmacokinetic models in risk assessment. In: Toxicoki-netics and Risk Assessment,edited by J. C. Lipscomb and E. V. Ohanian, pp. 123-140. Informa Health Care, New York.
267. Thrall, K. D., Soelberg, J. J., Weitz, K. K., and Woodstock, A. D. (2002): Development of a physiologically based pharmacokinetic model for methyl ethyl ketone in F344 rats. J. Toxicol. Environ. Health A, 65:881-896.
268. Timchalk, C., Kousba, A., and Poet, T. S. (2002): Monte Carlo analysis of the human chlorpyrifos-oxonase (PONI) polymorphism using a physiologically based pharmacok-inetic and pharmacodynamic (PBPK/PD) model. Toxicol. Lett, 135:51-59.
269. Travis, C. C., and Hattemer-Frey, H. A. (1991): Physiological pharmacokinetic models. In: Statistics in Toxicology, edited by D. Krewski and C. Franklin. Gordon and Breach, New York, p. 170.
270. U.S. EPA (1987): Update to the Health Risk Assessment Document and Addendum for Dichloromethane: Pharma-cokinetics, Mechanism of Action and Epidemiology, EPA 600/8-87/030A. U.S. Environmental Protection Agency, Washington, D.C.
271. U.S. EPA (1994): Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry, EPA 600/8-90/066F. Office of Research and Development, U.S. Environmental Protection Agency, Washington, D.C.
272. U.S. EPA (1999): Toxicological Review of Ethylene Glycol Monobutyl Ether: In Support of Summary Information on the IRIS, National Center for Environmental Assessment, U.S. Environmental Protection Agency, Washington, D.C. (http://www.epa.gov/iris).
273. U.S. EPA (2000): Toxicological Review of Vinyl Chloride: In Support of Summary Information on the IRIS, EPA/635/R-00/004. National Center for Environmental Assessment, U.S. Environmental Protection Agency, Washington, D.C. (http://www.epa.gov/iris).
274. U.S. EPA (2003): Toxicology Review of Xylenes: In Support of Summary Information on the IRIS, EPA/635/R-03/001. U.S. Environmental Protection Agency, Washington, D.C. (http://www.epa.gov/iris).
275. U.S. EPA (2006): Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment, EPA 600/R-05/043F. U.S. Environmental Protection Agency, Washington, D.C.
276. Van Asaperen, J., Rijcken, W. R. P., and Lammers, J. H. C. M. (2003): Application of physiologically based toxi-cokinetic modeling to study the impact of the exposure scenario on the toxicokinetics and the behavioural effects of toluene in rats. Toxicol. Lett., 138:51-68.
277. Van Eijkeren, J. C. H. (2003): Estimation of metabolic rate constants in PBPK-models from liver slice experiments: what are the experimental needs? Risk Anal., 22(1):159-173.
278. Vinegar, A. (2001): PBPK modeling of canine inhalation exposures to halogenated hydrocarbons. Toxicol. Sci., 60:20-27.
279. Vinegar, A., and Jepson, G. W. (1996): Cardiac sensitiza-tion thresholds of halon replacement chemicals predicted in humans by physiologically based pharmacokinetic modeling. Risk Anal, 16:571-579.
280. Wada, D. R., Stanski, D. R., and Ebling, W. F. (1995): A PC-based graphical simulator for physiological pharmacokinetic models. Comput. Meth. Programs Biomed., 46:245-255.
281. Wagner, J. G. (1975): Fundamentals of Clinical Pharmacokinetics. Drug Intelligence, Hamilton, IL.
282. Waller, C. L., Evans, M. V., and McKinney, J. D. (1996): Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. Drug Metab. Dispos., 24:203-210.
283. Wilkinson, G. R., and Shand, D. G. (1975): A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther, 18:377-390.
284. Wold, S. (1991): Validation of QSARs, QSAR, 10: 191-193.
285. Wünscher, G., Kersting, H., Heberer, H., Westmeier, I., Wenzel, V., Flechsig, M., and Matthaeus, E. (1991): Simulation system SONCHES-based toxicokinetic model and data bank as a tool in biological monitoring and risk assessment. Sci. Total Environ., 101:101-109.
286. You, L., Gazi, E. (1999): Archibeque-Engle, S., Casanova, M. Connolly, R. B., and Heck, H. A., Transplacental and lactational transfer of p,p'-DDE in Sprague-Dawley rats. Toxicol. Appl. Pharmacol., 157:134-144.